On July 1, 2014, Actavis (NYSE:ACT) completed the acquisition of Forest Laboratories, Inc., including Aptalis Pharmaceutical Technologies, creating one of the world’s fastest-growing specialty pharmaceutical companies. Visit www.Actavis.com to learn more.
The Aptalis Pharmaceutical Technologies business specializes in product development that leverages our proprietary pharmaceutical technologies.
We utilize these technologies to develop novel prescription and OTC products with our partners that are designed to have advantages over existing products and address unmet medical needs.
We continue to work with partners to develop and supply our licensed and manufactured products. Integrated R&D and manufacturing teams in the U.S. and Europe support projects from formulation through scale-up and commercial-scale manufacturing.
Our track record of commercialization success includes products that are marketed in more than 50 countries around the world by our partners.